INZY.Inozyme Pharma, INC
10-Q: Inozyme Pharma Reports Q1 2025 Results, Prioritizes ENPP1 Deficiency Program
Sentiment:
Quarterly Report
Inozyme Pharma is focusing on its ENPP1 Deficiency program after reporting a net loss of $28.0 million for the first quarter of 2025.
Capital raiseThe company states that its ability to fund its operations is dependent upon management's plan, which include raising additional capital through potential public or private equity financings, debt financings, collaboration agreements or other capital sources.The company's auditors have raised substantial doubt about the company's ability to continue as a going concern, which will likely require a capital raise.
Worse than expectedThe company reported a larger net loss in Q1 2025 compared to Q1 2024.The company's auditors have raised substantial doubt about the company's ability to continue as a going concern.
Summary
- Inozyme Pharma reported a net loss of $28.0 million for the three months ended March 31, 2025, compared to a net loss of $23.3 million for the same period in 2024.
- Research and development expenses increased to $20.4 million from $19.1 million year-over-year.
- The company is prioritizing its ENPP1 Deficiency program and has reduced its workforce by approximately 25%.
- As of March 31, 2025, Inozyme had cash, cash equivalents, and short-term investments of $84.8 million.
- The company believes these funds will support operations into the first quarter of 2026, but raises substantial doubt about the company's ability to continue as a going concern.
- Inozyme is seeking additional funding through potential equity or debt financings, collaboration agreements, or other capital sources.
- The company is advancing clinical trials for INZ-701, including the ENERGY 3 pivotal trial in pediatric patients with ENPP1 Deficiency, with topline data expected in the first quarter of 2026.
- The FDA and EMA have provided regulatory guidance supporting further clinical development of INZ-701 in children with ABCC6 Deficiency.
- The company is postponing any future trials in ABCC6 Deficiency and calciphylaxis.
Sentiment
Score: 4
Explanation: The document presents a mixed picture. While there are positive clinical developments and regulatory milestones, the financial results are concerning, and the company's ability to continue as a going concern is in doubt. The strategic reprioritization and workforce reduction also indicate challenges.
Positives
- The FDA and EMA have provided regulatory guidance supporting further clinical development of INZ-701 in children with ABCC6 Deficiency.
- The company received fast track designation from the FDA for INZ-701 for the treatment of calciphylaxis.
- The company announced positive interim data for INZ-701 in infants and young children with ENPP1 Deficiency.
- The company completed enrollment in the ENERGY 3 pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency.
- The company announced the appointment of Petra Duda, M.D., Ph.D., as Chief Medical Officer, effective May 15, 2025.
- The U.S. Centers for Medicare & Medicaid Services (CMS) has accepted a new set of ICD-10 diagnosis codes to support the classification of disorders of pyrophosphate metabolism, including ENPP1 Deficiency.
- The company reached an agreement with Japans Pharmaceuticals and Medical Devices Agency to accept ex-Japan clinical data for filing, without requiring Japanese patients.
- The company received EMA Orphan Designation to INZ-701 for the treatment of calciphylaxis.
Negatives
- The company reported a net loss of $28.0 million for Q1 2025, an increase from $23.3 million in Q1 2024.
- The company is postponing any future trials in ABCC6 Deficiency and calciphylaxis.
- The company reduced its workforce by approximately 25% as part of a strategic reprioritization.
- The company's auditors have raised substantial doubt about the company's ability to continue as a going concern.
Risks
- The company's ability to continue as a going concern is dependent on raising additional capital.
- The company is subject to risks related to clinical trial outcomes, regulatory approvals, and market acceptance of its product candidates.
- Changes in U.S. trade policy could negatively impact the company's costs and supply chain.
- The company is dependent on third-party manufacturers and contract research organizations (CROs).
- The company has a history of operating losses and may not achieve or sustain profitability.
Future Outlook
The company is prioritizing activities to support the planned BLA filing for INZ-701 for ENPP1 Deficiency and expects to commercially launch INZ-701 as early as the first half of 2027, pending regulatory approvals. The company is seeking additional funding to support its operations.
Management Comments
- Management believes that based on the Companys current cash, cash equivalents, and short-term investments as of March 31, 2025 and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about the Company's ability to continue as a going concern for one year after the date that these unaudited condensed consolidated financial statements are issued.
Industry Context
Inozyme is focused on developing therapies for rare diseases, a sector that often sees high unmet medical needs and potential for orphan drug designations, which can provide market exclusivity and other benefits. The company's focus on the PPi-Adenosine Pathway and its lead product candidate, INZ-701, positions it within the growing field of enzyme replacement therapies.
Comparison to Industry Standards
- Enzyme replacement therapies (ERTs) are a well-established treatment modality for certain rare genetic disorders, with companies like BioMarin, Sanofi Genzyme, and Alexion (now part of AstraZeneca) having successful ERT products on the market.
- Inozyme's approach of targeting the PPi-Adenosine Pathway is novel, but the company faces similar challenges to other biotech companies developing ERTs, including manufacturing complexities, immunogenicity risks, and high development costs.
- The company's decision to prioritize its ENPP1 Deficiency program and postpone other trials reflects a common strategy in the biotech industry to focus resources on the most promising assets and indications.
- The company's cash runway into Q1 2026 is relatively short compared to some other biotech companies in late-stage development, highlighting the need for additional funding.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Medical Officer | Kurt Gunter, M.D. | Petra Duda, M.D., Ph.D. | 2025-05-15 | Retirement |
Stakeholder Impact
- Shareholders face uncertainty due to the company's financial challenges and need for additional funding.
- Employees have been impacted by the workforce reduction.
- Patients with ENPP1 Deficiency may benefit from the continued development of INZ-701.
- Suppliers and creditors may face increased risk due to the company's financial situation.
Next Steps
- The company plans to continue advancing its clinical trials for INZ-701, particularly the ENERGY 3 pivotal trial in pediatric patients with ENPP1 Deficiency.
- The company is preparing for a potential BLA filing for INZ-701 for ENPP1 Deficiency.
- The company is seeking additional funding through potential equity or debt financings, collaboration agreements, or other capital sources.
Key Dates
| Date | Description |
|---|---|
| 2017-01 | Inozyme entered into a license agreement with Yale University. |
| 2020-05 | Amendment to the license agreement with Yale University. |
| 2020-07 | Amendment to the license agreement with Yale University. |
| 2020-07-17 | Stockholders approved the 2020 Stock Incentive Plan. |
| 2020-07-23 | The 2020 Stock Incentive Plan became effective. |
| 2021-08-11 | The company filed a universal shelf registration statement on Form S-3. |
| 2021-08-23 | The 2021 Registration Statement was declared effective. |
| 2021-11 | Initiated Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 Deficiency. |
| 2022-01 | Paid Yale an approximately $0.3 million milestone payment following dosing of the first patient in the Companys Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 Deficiency in November 2021. |
| 2022-02 | Amendment to the sponsored research agreement with Yale University. |
| 2022-03 | Paid Yale an approximately $0.3 million milestone payment following completion of the first cohort of the Company's Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 Deficiency in January 2022. |
| 2022-04 | Initiated Phase 1/2 clinical trial of INZ-701 in adult patients with ABCC6 Deficiency. |
| 2022-05 | Amendment to the sponsored research agreement with Yale University. |
| 2022-07-25 | Entered into a loan and security agreement with K2 HealthVentures LLC. |
| 2023-02 | Reported interim pharmacokinetic, pharmacodynamic, and safety data from the Phase 1/2 trial of INZ-701 in adult patients with ENPP1 Deficiency. |
| 2023-02 | Dosed first pediatric patient with ENPP1 Deficiency with INZ-701 under expanded access program. |
| 2023-02-27 | The Company's board of directors adopted the 2023 Inducement Stock Incentive Plan. |
| 2023-06 | Dosed the first infant patient in the ENERGY 1 trial. |
| 2023-06 | Borrowed $7.5 million under the second tranche commitment. |
| 2023-07 | Announced a regulatory update for our global development strategy of INZ-701 for the treatment of ENPP1 Deficiency following meetings with the FDA and the Paediatric Committee of the EMA (PDCO). |
| 2023-07 | Completed a scientific advice procedure and reached alignment with the Committee for Medicinal Products for Human Use (CHMP) regarding our global development strategy. |
| 2023-07-27 | Entered into an underwriting agreement with BofA Securities, Inc., Cowen and Company, LLC and Piper Sandler & Co., as representatives of the several underwriters named therein (collectively, the Underwriters), relating to an underwritten public offering of 14,375,000 shares of the Company's common stock. |
| 2023-08-01 | The closing of the offering took place. |
| 2023-09 | Opened the first site for the ENERGY 3 trial. |
| 2023-11-07 | The company filed a universal shelf registration statement on Form S-3. |
| 2023-11-15 | The 2023 Registration Statement was declared effective. |
| 2023-12 | Borrowed $12.5 million under the third tranche commitment. |
| 2024-01 | Amendment to the sponsored research agreement with Yale University. |
| 2024-02 | Initiated SEAPORT 1, a Phase 1 clinical trial designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of INZ-701 in patients with ESKD receiving hemodialysis. |
| 2024-03 | Incurred and paid a $0.5 million milestone payment following completion of dosing of the first patient in the Companys pivotal clinical trial of INZ-701 in pediatric patients with ENPP1 Deficiency. |
| 2024-04 | Reported positive topline safety, pharmacokinetic, pharmacodynamic, and exploratory efficacy data from the Phase 1/2 trial of INZ-701 in adult patients with ENPP1 Deficiency. |
| 2024-06 | Initiated ADAPT, a multicenter, open-label, long-term safety trial of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Deficiency who have received INZ-701 in an existing clinical trial and choose to continue dosing with INZ-701. |
| 2024-06 | SEAPORT 1 was fully enrolled. |
| 2024-08-06 | Filed a prospectus supplement under the 2023 Registration Statement to register the offer and sale of the outstanding shares that could be sold under the At-the-Market Offering Program. |
| 2024-10 | Announced positive interim data from SEAPORT 1. |
| 2024-12 | Amendment to the sponsored research agreement with Yale University. |
| 2024-Q4 | Opened the first site for the ENERGY 2 trial. |
| 2024-Q4 | The last patients last visit occurred in the fourth quarter of 2024. |
| 2025-01 | Received fast track designation from the FDA for INZ-701 for the treatment of calciphylaxis. |
| 2025-01 | Announced positive interim data for INZ-701 in infants and young children with ENPP1 Deficiency. |
| 2025-01 | Announced regulatory guidance from the FDA and EMA supporting further clinical development of INZ-701 in children with ABCC6 Deficiency. |
| 2025-01 | Completed enrollment in the ENERGY 3 pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency. |
| 2025-03 | Announced strategic reprioritization of activities to support the planned BLA filing for INZ-701 for our lead indication, ENPP1 Deficiency. |
| 2025-03 | Announced a reprioritization to focus resources on its ENPP1 Deficiency program, which resulted in a reduction of the Companys workforce by approximately 25 % across all areas of the Company. |
| 2025-04 | Received EMA Orphan Designation to INZ-701 for the treatment of calciphylaxis. |
| 2025-04 | Announced a publication in JBMR Plus titled, Phenotypic characterization of ENPP1 deficiency: generalized arterial calcification of infancy and autosomal recessive hypophosphatemic rickets type 2. |
| 2025-05 | Announced interim anti-drug antibody (ADA) and serum phosphate data from the ENERGY 3 pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, based on an interim evaluation conducted as part of ongoing safety monitoring. |
| 2025-05 | Announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has accepted a new set of ICD-10 diagnosis codes to support the classification of disorders of pyrophosphate metabolism, including ENPP1 Deficiency. |
| 2025-05 | Reached an agreement with Japans Pharmaceuticals and Medical Devices Agency to accept ex-Japan clinical data for filing, without requiring Japanese patients. |
| 2025-05 | Announced the appointment of Petra Duda, M.D., Ph.D., as Chief Medical Officer, effective May 15, 2025. |
| 2026-Q1 | Expect topline data to follow in the first quarter of 2026 from the ENERGY 3 pivotal trial. |
| 2027-H1 | Expect to commercially launch INZ-701 as early as the first half of 2027. |
Keywords
INZ-701, ENPP1 Deficiency, ABCC6 Deficiency, Calciphylaxis, Clinical Trials, Biologics License Application, PPi-Adenosine Pathway, Rare Diseases, Financial Results, Inozyme Pharma
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.